piperacillin

Piperacillin is a ureidopenicillin, an extended-spectrum penicillin that extends coverage beyond standard penicillins to include many gram-negative organisms (including Pseudomonas aeruginosa), gram-positive organisms, and anaerobes. Like all beta-lactams, it inhibits bacterial cell wall synthesis by binding penicillin-binding proteins (transpeptidases), preventing cross-linking of peptidoglycan, leading to cell lysis and death (bactericidal, time-dependent killing).

Piperacillin is almost always administered combined with tazobactam, a beta-lactamase inhibitor that protects piperacillin from hydrolysis by bacterial beta-lactamases, thereby broadening its spectrum to include many beta-lactamase-producing organisms (e.g., some strains of E. coli, Klebsiella, Enterobacter, anaerobes like Bacteroides fragilis).

Clinical uses (Piperacillin-tazobactam, "Zosyn"): empiric coverage for nosocomial/hospital-acquired infections, febrile neutropenia, intra-abdominal infections, polymicrobial infections, diabetic foot infections, hospital-acquired pneumonia, and sepsis of unknown source — valued for broad gram-negative (including Pseudomonas), gram-positive, and anaerobic coverage.

Mechanism/Pharmacology: Beta-lactam ring binds and inactivates PBPs (transpeptidases) that cross-link peptidoglycan strands in the bacterial cell wall; triggers autolysins leading to cell lysis. No intrinsic activity against MRSA, atypicals (Mycoplasma, Chlamydia, Legionella), or many resistant beta-lactamase producers without tazobactam.

Adverse effects: Hypersensitivity reactions (rash to anaphylaxis), interstitial nephritis, hemolytic anemia, GI upset, and notably a reported association with renal injury when combined with vancomycin (synergistic nephrotoxicity risk cited in recent literature, relevant for Step 2 management questions in ICU settings). Can cause electrolyte disturbances (hypokalemia) due to sodium salt formulation and nonabsorbable anion effect. Platelet dysfunction at high doses (reversible, dose-dependent, relevant in uremic/critically ill patients).

Resistance: Beta-lactamase production (addressed by tazobactam), altered PBPs (e.g., in MRSA—mecA gene encoding PBP2a—not covered by piperacillin-tazobactam), efflux pumps and porin mutations in Pseudomonas.

High-yield test points: Know piperacillin-tazobactam's broad spectrum (gram+, gram-, anaerobes, Pseudomonas), its combination with beta-lactamase inhibitor, lack of MRSA/atypical coverage, and its common use in empiric therapy of serious nosocomial infections. Recognize the piperacillin-tazobactam + vancomycin nephrotoxicity controversy as a testable clinical pearl.